Development of a Sensitive Outcome for Economical Drug Screening for Progressive Multiple Sclerosis Treatment. - Wikidata - wikimedia - TriplyDB

Development of a Sensitive Outcome for Economical Drug Screening for Progressive Multiple Sclerosis Treatment.

Development of a Sensitive Outcome for Economical Drug Screening for Progressive Multiple Sclerosis Treatment.

http://www.wikidata.org/entity/Q37172794

about

Finger and foot tapping as alternative outcomes of upper and lower extremity function in multiple sclerosis.Comparative utility of disability progression measures in PPMS: Analysis of the PROMiSe data set.Pharmacodynamic effects of daclizumab in the intrathecal compartment.New Multiple Sclerosis Disease Severity Scale Predicts Future Accumulation of Disability.Therapies: Progressive steps.Perspective: Who dares, wins.Clinical trial design for progressive MS trials.NeurEx: digitalized neurological examination offers a novel high-resolution disability scale Identifying and Quantifying Neurological Disability via Smartphone

P2860

Q33455446-100C2B18-B23C-48B3-A746-81DF2B0D73F2 Q33848186-C5C55645-3773-4548-8857-8B865991FC71 Q40962441-5220FA6F-36B2-4AEE-8083-E592C91D158B Q45974017-EC797D59-A57E-406C-BF47-ED10E5547FE5 Q47367518-4479E25A-1D56-41D3-B8F1-D879D305574F Q47379142-610CAFD1-5CF4-49F3-9094-156DA01ECFB3 Q50084584-EAD2F448-F40A-4F69-9A67-F2FD9DF02228 Q57821586-3C2CB992-0819-49DC-8398-0D606304E00E Q58764825-F9237A26-BB30-4549-9499-FCAAA8D68C5B

P2860

Development of a Sensitive Outcome for Economical Drug Screening for Progressive Multiple Sclerosis Treatment.

http://www.wikidata.org/entity/Q37172794

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 15 August 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Development of a Sensitive Out ...... Multiple Sclerosis Treatment.

@en

Development of a Sensitive Out ...... Multiple Sclerosis Treatment.

@nl

type

label

Development of a Sensitive Out ...... Multiple Sclerosis Treatment.

@en

Development of a Sensitive Out ...... Multiple Sclerosis Treatment.

@nl

prefLabel

Development of a Sensitive Out ...... Multiple Sclerosis Treatment.

@en

Development of a Sensitive Out ...... Multiple Sclerosis Treatment.

@nl

P1433

Q37172794-42F1BEB2-1177-4A1C-B081-423C9DC8FFD7

P1476

Q37172794-9906F8EF-02AB-437D-AF26-F11E1FAE6F82

P2093

Q37172794-1402BB5A-EE0C-4CF3-8881-27363FDAB316

Q37172794-1CF32C31-6AD2-4B0E-8499-C7B90A20778E

Q37172794-1FCCBD88-88E8-45A9-9E03-D3B46F781C41

Q37172794-237E3EF9-161B-4C72-9135-062AF1BE9C88

Q37172794-2D87F758-EEBE-4187-B053-535C2385A452

Q37172794-3ED7B3CE-86D9-437E-A9A2-2C4865A3FC57

Q37172794-61A0500D-EC08-499F-B63D-371AF1375B40

Q37172794-68E3B7F7-9E71-492A-9452-5479A88D3E33

Q37172794-78EAE5A6-1362-4F60-AF5F-CE98E1302316

Q37172794-8F2F5CE0-289C-4849-8BE8-49B2655008D3

P2860

Q37172794-0567CF70-E2CC-404A-AD89-0327F4F2C700

Q37172794-0AB2B45E-B85A-4281-975A-70504DB6A0D9

Q37172794-1385D74F-3DFF-4A18-98D2-1DB1225E39B1

Q37172794-2171B153-3D43-4EAC-9629-7FA95095D20D

Q37172794-34CA5297-AC2E-4114-844D-226953BE7FE4

Q37172794-354FF83B-0E33-4ADA-9C2E-37FACBF5D64F

Q37172794-367C052C-E8F9-423D-8753-904D88F5D480

Q37172794-4039848F-E84A-4ADE-8722-981D681614FD

Q37172794-49ADA683-C212-4614-9CD0-9D6CC0F8231C

Q37172794-4B75D69B-06AA-4FA3-9DB1-BA2C0F275616

P304

Q37172794-20135BB6-16D5-4762-9CC1-86ED3E5F1367

P31

Q37172794-42D9AA6F-D92B-4BE3-B4DF-9CB0E315A5A0

P356

Q37172794-66F069B7-E633-4EBD-9616-032744B8BFCA

P478

Q37172794-353572B9-60AF-45FC-B1CB-1787FD092B8B

P50

Q37172794-030B08BE-22BC-4558-9B8F-7740049617F1

Q37172794-FFDBBFF8-9DCA-412A-AEC4-9C002A24CA0C

P577

Q37172794-62E3D1C5-36B0-4B31-AD06-C8FB0D81AD32

P698

Q37172794-08AB5552-F6ED-4E22-85DE-C94DAA7DFAC8

P921

Q37172794-3E1F2150-13BD-4EF8-A4E2-0EB26517B2FC

Q37172794-6787A012-19EA-499E-BB4E-DC1DE359AE39

P932

Q37172794-7838BCA3-2B2A-4A7A-88D9-5B12726E09AA

P356

FNEUR.2016.00131

P1433

Frontiers in Neurology

P1476

Development of a Sensitive Out ...... e Multiple Sclerosis Treatment

@en

P2093

Bibiana Bielekova

http://www.w3.org/2001/XMLSchema#string

Blake Snyder

http://www.w3.org/2001/XMLSchema#string

Chris Barbour

http://www.w3.org/2001/XMLSchema#string

Irene Cortese

http://www.w3.org/2001/XMLSchema#string

Joan Ohayon

http://www.w3.org/2001/XMLSchema#string

Kaylan Fenton

http://www.w3.org/2001/XMLSchema#string

Makoto Tanigawa

http://www.w3.org/2001/XMLSchema#string

Mark Greenwood

http://www.w3.org/2001/XMLSchema#string

Peter Kosa

http://www.w3.org/2001/XMLSchema#string

Tanya Lehky

http://www.w3.org/2001/XMLSchema#string

P2860

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial

Accurate, robust, and automated longitudinal and cross-sectional brain change analysis.

Magnetic resonance spectroscopy markers of disease progression in multiple sclerosis.

Low-dose (7.5 mg) oral methotrexate for chronic progressive multiple sclerosis. Design of a randomized, placebo-controlled trial with sample size benefits from a composite outcome variable including preliminary data on toxicity.

Finding the Elusive Psychiatric "Lesion" With 21st-Century Neuroanatomy: A Note of Caution.

Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis.

A topology-preserving approach to the segmentation of brain images with multiple sclerosis lesions.

Twenty-five pitfalls in the analysis of diffusion MRI data.

The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force.

P304

131

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FNEUR.2016.00131

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-08-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27574516

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis

P932

4983704

http://www.w3.org/2001/XMLSchema#string